http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100955669-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-35 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-616 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-60 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-35 |
| filingDate | 2008-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2010-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2010-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-100955669-B1 |
| titleOfInvention | Combination preparations containing HMBCCA reductase inhibitors and aspirin and preparation methods thereof |
| abstract | The present invention relates to a combination preparation for the treatment and prevention of cardiovascular diseases using the time difference dosing principle, and more particularly to a combination containing aspirin and HMG-CoA reductase inhibitors such as simvastatin. The combination of the HMG-CoA reductase inhibitor and aspirin according to the present invention is developed based on the principle of time difference dosing, which shows a much better cardiovascular disease treatment and prophylaxis than each or simultaneous administration, and is a once-daily dosage form. Improve patient compliance. In particular, the combination according to the present invention, despite reducing the side effects by reducing the dose of aspirin, platelet aggregation inhibitory effect shows the same effect as the existing normal dose and at the same time shows a blood pressure-lowering effect of aspirin. In addition, the combination preparation according to the present invention secured the stability, safety and efficacy aspects of the human body to enable long-term storage of two drugs showing mutual instability.n n n n Time difference dosing principle, simvastatin, aspirin, combination |
| priorityDate | 2007-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 149.